Donald Trump made 3,700 stock trades in just 90 days. Why Wall Street is shocked

Financial disclosures show Donald Trump or his advisers executed more than 3,700 stock trades in the first three months of 2026, including at least $1 million purchases in Nvidia, Oracle, Microsoft, Boeing and Costco and a $5 million to $25 million sale in Microsoft, Meta and Amazon on February 10. The activity has intensified conflict-of-interest scrutiny because several holdings sit in sectors directly affected by U.S. policy, including AI export controls, antitrust, defense and media regulation. The White House denied wrongdoing, but the scale and timing are likely to keep governance and ethics concerns in focus.

Analysis

The market implication is not the ethics headline itself, but the implied information asymmetry premium embedded in policy-sensitive megacaps. When a political principal is an active allocator across AI, defense, media, and telecom names, the discount rate on regulatory outcomes rises for the whole sector: investors will demand a higher risk premium on any company exposed to export controls, antitrust, procurement, or communications policy. That is modestly negative for the obvious names, but the bigger second-order effect is that “Washington beta” becomes a factor in valuation models, especially for firms where policy can move forward multiples more than fundamentals.

Within the basket, the cleaner relative losers are the most policy-levered balance-sheet-light growth names, where a headline-driven derating can outlast any actual earnings impact. AI infrastructure suppliers and large platform companies are vulnerable to a short-term sentiment air pocket over the next 1-4 weeks, while defense/aerospace and regulated incumbents are less exposed to narrative damage but could still see elevated scrutiny on contract awards and enforcement risk over the next 1-3 quarters. The surprising relative beneficiary may be Oracle: its policy sensitivity is lower than the other software/AI beneficiaries, so it can absorb some of the same AI enthusiasm with less direct regulatory overhang.

The contrarian read is that this may be overinterpreted as a trading signal for the mentioned names when the more durable trade is actually in governance and process names: the more the market obsesses over conflicted trading, the more boards, brokers, and custodians tighten controls around politically exposed persons, which is a subtle tailwind for compliance, surveillance, and risk-management vendors. The bigger tail risk is not the disclosures themselves but a new enforcement or legislation cycle that turns this into a multi-month headline overhang, compressing multiples for the entire politically sensitive cohort. If that cycle stalls, the stocks likely mean-revert quickly because the underlying earnings trajectory for most of these companies is still intact.

Key Decisions for Investors

• Short NVDA/MSFT/AMZN basket against long ORCL for 2-6 weeks: same AI/cloud exposure, but ORCL has less direct antitrust/export-control overhang; target 3-5% relative outperformance if Washington risk premium widens.
• Buy puts or put spreads on META and NVDA into any strength over the next 1-3 weeks: these names have the highest headline sensitivity to regulation and China export controls; use defined-risk structures to cap losses if the story fades.
• Long BA on a 1-3 month horizon versus short a policy-sensitive mega-cap pair (e.g., MSFT or AMZN): defense and aerospace demand is less exposed to reputational governance pressure and may benefit if procurement scrutiny increases for peers.
• Start a small long in compliance/risk tooling proxies via large-cap software quality names if available in-house universe; the thesis is a 6-12 month rise in surveillance and governance spend as PEP controls tighten.
• Avoid adding fresh gross exposure to the full listed basket until the next filing cycle or policy hearing: headline risk is high while fundamental earnings revisions are low, making the near-term reward/risk unfavorable on an outright long basis.